Pancragen vs Survodutide
A side-by-side research comparison of Pancragen and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pancragen | Survodutide |
|---|---|---|
| Full name | Pancragen (Lys-Glu-Asp-Trp Pancreas Bioregulator) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (peptide bioregulator) | Phase 3 Clinical Trial |
| Mechanism | As a signal peptide (Lys-Glu-Asp-Trp), it is proposed to regulate gene expression in pancreatic tissue, supporting normal endocrine and exocrine pancreatic function and carbohydrate metabolism. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | ~575 Da | 4,500 Da (approximate) |
| Half-life | Short (peptide) | 5-7 days |
| Bioavailability | Oral (encapsulated) or subcutaneous | High (SubQ) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 0.6-6.0 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral capsule or subcutaneous | Subcutaneous |
Pancragen reported benefits
- Pancreatic tissue support
- Carbohydrate metabolism support (proposed)
- Metabolic resilience
- Short course-based protocol
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.